Immuno-oncology SYS-6045 cleared for clinic in China for advanced solid tumors Jan. 8, 2025 CSPC Pharmaceutical Group Ltd.’s antibody-drug conjugate SYS-6045 has been granted clearance by China’s National Medical Products Administration (NMPA) to enter clinical trials.Read More